Literature DB >> 1611720

Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts.

C A Feghali1, K L Bost, D W Boulware, L S Levy.   

Abstract

The effect of human recombinant interleukin-4 (hrIL-4) on normal human adult dermal fibroblasts in terms of proliferation and IL-6 production was studied. Fibroblasts were exposed to different concentrations of IL-4 for various periods of time. Proliferation was measured using a [3H]thymidine incorporation assay. IL-6 production was measured at the transcriptional, protein, and functional levels by Northern blot analysis, radioimmunoassay, and B9 bioassay, respectively. Our results show that hrIL-4 significantly stimulated (two- to fivefold) fibroblasts to increase the incorporation of [3H]thymidine in a dose- and time-dependent manner. However, hrIL-1, hrIL-2, hrIL-5, or hrTNF alpha, at the same concentration (100 U/ml) and for the same time period (4 days), did not. In addition, IL-4 significantly induced (four- to eightfold) the production of immunoreactive and biologically functional IL-6. However, IL-4 was not as potent an inducer of IL-6 as IL-1. The IL-4-induced IL-6 production was dose and time dependent and was due, at least in part, to a dramatic increase in the steady-state levels of IL-6 mRNA. This is the first report describing the ability of IL-4 to activate human dermal fibroblasts in terms of proliferation and IL-6 production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611720     DOI: 10.1016/0090-1229(92)90011-c

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  10 in total

Review 1.  Interleukin 4 in systemic sclerosis: not just an increase.

Authors:  S P Atamas; B White
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 4.  Evaluation and management of pulmonary fibrosis in scleroderma.

Authors:  Barbara White
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 5.  Mast cells in airway diseases and interstitial lung disease.

Authors:  Glenn Cruse; Peter Bradding
Journal:  Eur J Pharmacol       Date:  2015-05-08       Impact factor: 4.432

6.  The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome.

Authors:  Anne Corbould; Andrea Dunaif
Journal:  Metabolism       Date:  2007-05       Impact factor: 8.694

7.  M2 macrophages have unique transcriptomes but conditioned media does not promote profibrotic responses in lung fibroblasts or alveolar epithelial cells in vitro.

Authors:  Elissa M Hult; Stephen J Gurczynski; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-07-07       Impact factor: 6.011

8.  Systemic sclerosis biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.

Authors:  Ryan T Kendall; Ludivine Renaud; John E Baatz; Maya Malaab; Xinh-Xinh Nguyen; Carol A Feghali-Bostwick
Journal:  J Proteomics       Date:  2021-04-27       Impact factor: 3.855

Review 9.  The aetiopathogenesis of systemic sclerosis: thick skin--thin hypotheses. The Parkes Weber Lecture 1994.

Authors:  C M Black
Journal:  J R Coll Physicians Lond       Date:  1995 Mar-Apr

Review 10.  Role of Mast Cells and Type 2 Innate Lymphoid (ILC2) Cells in Lung Transplantation.

Authors:  Esmaeil Mortaz; Saeede Amani; Sharon Mumby; Ian M Adcock; Mehrnaz Movassaghi; Jelle Folkerts; Johan Garssen; Gert Folkerts
Journal:  J Immunol Res       Date:  2018-10-30       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.